COPD Clinical Trials in Florida

25 recruiting studies across 4 cities

Browse by City

Miami

All Trials in Florida

Phase

Trial	Phase	Sponsor	Dist.
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease	Phase 2	AstraZeneca	<1 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)	Phase 3	AstraZeneca	<1 mi
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3	N/A	Apreo Health, Inc.	<1 mi
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home	N/A	Temple University	<1 mi
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD	Phase 2	Johns Hopkins University	<1 mi
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD	N/A	Nuvaira, Inc.	<1 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype	Phase 3	Sanofi	<1 mi
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)	Phase 3	GlaxoSmithKline	<1 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype	Phase 3	Sanofi	<1 mi
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease	Phase 3	AstraZeneca	<1 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)	Phase 3	AstraZeneca	<1 mi
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation	Phase 3	GlaxoSmithKline	<1 mi
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema	N/A	Pulmonx Corporation	<1 mi
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease	Phase 2/3	Pfizer	<1 mi
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.	Phase 4	Sanofi	<1 mi
Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD	N/A	University of Miami	<1 mi
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)	Phase 3	GlaxoSmithKline	<1 mi
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment	Phase 2	Expedition Therapeutics, Inc	<1 mi
Rademikibart IV for Acute Asthma and COPD Exacerbation	Phase 2	Connect Biopharm LLC	<1 mi
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening	—	Freenome Holdings Inc.	5 mi
STRIVE Post-Market Registry Study	—	Olympus Corporation of the Americas	6 mi
Alpha-1 Research Registry	—	Alpha-1 Foundation	6 mi
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)	Phase 3	GlaxoSmithKline	11 mi
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD	Phase 2	Altesa Biosciences, Inc.	13 mi
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)	Phase 2	Windward Bio	13 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.